Datamonitor Healthcare Crohn’s Disease KOL Interviews
Datamonitor Healthcare Crohn’s Disease KOL Interviews
$599.00
Datamonitor Healthcare interviewed two inflammatory bowel disease experts, one based in France and the other in Italy, to gauge their views on marketed drugs for Crohn’s disease (CD), late-stage clinical candidates, treatment challenges and unmet needs and the future treatment of CD.
Publisher: Pharma Intelligence
- Description
- Samples
April 05, 2017
Datamonitor Healthcare interviewed two inflammatory bowel disease experts, one based in France and the other in Italy, to gauge their views on marketed drugs for Crohn’s disease (CD), late-stage clinical candidates, treatment challenges and unmet needs and the future treatment of CD. The drugs discussed are listed below. The two interviews were combined into a single report.
Azasan (VRX), Cimzia, Cx601 (TIG), Entocort EC (PRGO), Entyvio (TKPYY), etrolizumab (RHHBF), filgotinib (GILD), GED 0301 (CELG), Humira (ABBV), Remicade (JNJ), Stelara (JNJ), Tysabri (BIIB), Xeljanz/Xeljanz XR (PFE).
Crohn’s Disease – sample page 3
Crohn’s Disease – sample page 4
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Immuno-Oncology Deal Trends, 2012–16 
Sign up to the